Adverse reactions

CONTACT GSK 1-877-512-1344

Learn more about reported common adverse reactions

Across two 12-week studies, the most commonly reported adverse reactions with ≥1% incidence and more common than FF/VI were:

Adverse Reactions TRELEGY
FF/VI 100/25
Nervous system disorders
Headache 4 3
Dysgeusia 2 <1
Musculoskeletal and connective tissue disorders
Back pain 4 2
Respiratory, thoracic, and mediastinal disorders
Cough 1 <1
Oropharyngeal pain 1 0
Gastrointestinal disorders
Diarrhea 2 <1
Infections and infestations
Gastroenteritis 1 0

Long-term Safety Data

In addition to the adverse reactions shown in the table above, adverse reactions occurring in ≥1% of the subjects treated with TRELEGY ELLIPTA (n=4151) for up to 52 weeks also included upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, urinary tract infection, and dysphonia.

Keep samples on hand to get patients started on TRELEGY


Stay up-to-date with new information on

trelegy ellipta